Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung CancerMotoko Tachihara, Kayoko Tsujino, Takeaki Ishihara et al.|JAMA Oncology|2023Cited by 68
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung CancerYoshimasa Shiraishi, Isamu Okamoto, Junji Kishimoto et al.|JAMA Oncology|2023Cited by 52
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Isamu Okamoto, Shogo Nomura et al.|The Lancet Respiratory Medicine|2024Cited by 43
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)Akito Hata, Tomohide Tamura, Yoshimasa Shiraishi et al.|Oncology and Therapy|2022Cited by 17
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung CancerYoshimasa Shiraishi, Isamu Okamoto, Junji Kishimoto et al.|Clinical Lung Cancer|2020Cited by 15